Novo Nordisk A/S (NVO) Financials

NYSE:NVO

Market Cap

836.84B

Total Revenue

176.95B

Gross Profit

148.51B

Operating Income

74.81B

Net Income

55.52B

Metric	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
revenue	83,572,000,000	88,806,000,000	107,927,000,000	111,780,000,000	111,696,000,000	111,831,000,000	122,021,000,000	126,946,000,000	140,800,000,000	176,954,000,000
costOfRevenue	14,140,000,000	14,562,000,000	16,188,000,000	17,183,000,000	17,632,000,000	17,617,000,000	20,088,000,000	20,932,000,000	23,658,000,000	28,448,000,000
grossProfit	69,432,000,000	74,244,000,000	91,739,000,000	94,597,000,000	94,064,000,000	94,214,000,000	101,933,000,000	106,014,000,000	117,142,000,000	148,506,000,000
researchAndDevelopmentExpenses	11,733,000,000	13,762,000,000	13,608,000,000	14,563,000,000	14,014,000,000	14,805,000,000	14,220,000,000	15,462,000,000	17,772,000,000	24,047,000,000
sellingAndMarketingExpenses	23,380,000,000	23,223,000,000	28,312,000,000	28,377,000,000	28,340,000,000	29,397,000,000	31,823,000,000	32,928,000,000	37,008,000,000	46,217,000,000
generalAndAdministrativeExpenses	3,508,000,000	3,537,000,000	3,857,000,000	3,962,000,000	3,784,000,000	3,916,000,000	4,007,000,000	3,958,000,000	4,050,000,000	4,467,000,000
sellingGeneralAndAdministrativeExpenses	26,888,000,000	26,760,000,000	32,169,000,000	32,339,000,000	32,124,000,000	33,313,000,000	35,830,000,000	36,886,000,000	41,058,000,000	50,684,000,000
operatingExpenses	37,939,000,000	39,752,000,000	42,295,000,000	46,165,000,000	45,097,000,000	46,966,000,000	49,450,000,000	51,888,000,000	58,498,000,000	73,697,000,000
operatingIncome	31,493,000,000	34,492,000,000	49,444,000,000	48,432,000,000	48,967,000,000	47,248,000,000	52,483,000,000	54,126,000,000	58,644,000,000	74,809,000,000
totalOtherIncomeExpensesNet	332,000,000	-347,000,000	-5,869,000,000	-536,000,000	-198,000,000	473,000,000	-3,930,000,000	-996,000,000	436,000,000	-5,747,000,000
ebitda	35,061,000,000	38,094,000,000	52,488,000,000	51,616,000,000	52,164,000,000	51,164,000,000	57,791,000,000	60,215,000,000	67,556,000,000	82,040,000,000
depreciationAndAmortization	2,799,000,000	3,435,000,000	2,959,000,000	3,193,000,000	3,182,000,000	3,925,000,000	5,308,000,000	6,089,000,000	8,912,000,000	7,231,000,000
interestIncome	56,000,000	167,000,000	85,000,000	52,000,000	69,000,000	51,000,000	65,000,000	337,000,000	2,887,000,000	239,000,000
interestExpense	55,000,000	563,000,000	6,046,000,000	65,000,000	90,000,000	85,000,000	220,000,000	390,000,000	2,451,000,000	378,000,000
incomeBeforeTax	32,539,000,000	34,096,000,000	43,483,000,000	47,798,000,000	48,680,000,000	47,615,000,000	48,553,000,000	53,130,000,000	59,080,000,000	69,062,000,000
incomeTaxExpense	7,355,000,000	7,615,000,000	8,623,000,000	9,873,000,000	10,550,000,000	8,987,000,000	9,602,000,000	10,992,000,000	11,323,000,000	13,537,000,000
netIncome	25,184,000,000	26,481,000,000	34,860,000,000	37,925,000,000	38,130,000,000	38,628,000,000	38,951,000,000	42,138,000,000	47,757,000,000	55,525,000,000
eps	9.4	10.1	13.56	14.99	15.42	15.96	16.41	18.05	20.79	24.51
epsdiluted	9.35	10.07	13.52	14.96	15.39	15.93	16.38	18.01	20.74	24.44
weightedAverageShsOut	2,679,362,000	2,621,881,188	2,570,796,460	2,529,945,000	2,473,218,000	2,419,603,000	2,374,299,000	2,333,900,000	2,296,600,000	2,265,300,000
weightedAverageShsOutDil	2,693,625,000	2,629,692,155	2,578,402,367	2,534,729,000	2,478,093,000	2,424,417,000	2,378,658,000	2,340,000,000	2,303,100,000	2,272,300,000
costAndExpenses	52,079,000,000	54,314,000,000	58,483,000,000	63,348,000,000	62,729,000,000	64,583,000,000	69,538,000,000	72,820,000,000	82,156,000,000	102,145,000,000
otherExpenses	-682,000,000	-770,000,000	-3,482,000,000	-737,000,000	-1,041,000,000	-1,152,000,000	-600,000,000	-460,000,000	-332,000,000	-1,034,000,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Bagsvaerd, , DK

Website

novonordisk.com

CEO

Mr. Lars Fruergaard Jorgensen

Employees

59337

About the Company

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.